Niacin metabolism and Parkinson's disease

Environmental Health and Preventive Medicine

Volumn 10, Issue 1, 2005, Pages 3-8

  Fukushima, Tetsuhito ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

1 methylnicotinamide; Complex I; Mitochondria; Nicotinamide N methyltransferase; Poly(ADP ribosyl) ation

Indexed keywords

1 METHYLNICOTINAMIDE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; HYDROXYL RADICAL; MITOCHONDRIAL DNA; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE METHYLTRANSFERASE; NICOTINIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUPEROXIDE;

ADENOSINE DIPHOSPHATE RIBOSYLATION; BRAIN; CYTOPLASM; DNA DAMAGE; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME DEGRADATION; HEREDITY; HUMAN; METABOLISM; METHYLATION; MITOCHONDRION; NERVE CELL NECROSIS; NICOTINIC ACID DEFICIENCY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; REVIEW;

EID: 14544284184     PISSN: 1342078X     EISSN: None     Source Type: Journal    
DOI: 10.1265/ehpm.10.3     Document Type: Review

References (59)

1. Scheffler IE. Mitochondria make a come back. Adv Drug Deliv Rev. 2001; 49: 3-26.
2. Fall PA, Fredrikson M, Axelson O, Granerus AK. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Mov Disord. 1999; 14: 28-37.
3. Hellenbrand W, Boeing H, Robra BP, Seidler A, Vieregge P, Nischan P, Joerg J, Oertel WH, Schneider E, Ulm G. Diet and Parkinson's disease. II: A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology. 1996; 47: 644-650.
4. Abbott RD, Ross GW, White LR, Sanderson WT, Burchfiel CM, Kashon M, Sharp DS, Masaki KH, Curb JD, Petrovitch H. Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. J Neurol. 2003; 250 (Suppl 3): III30-39.
5. Johnson CC, Gorell JM, Rybicki BA, Sanders K, Peterson EL. Adult nutrient intake as a risk factor for Parkinson's disease. Int J Epidemiol. 1999; 28: 1102-1109.
6. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000; 283: 2674-2679.
7. Pearl SM, Antion MD, Stanwood GD, Jaumotte JD, Kapatos G, Zigmond MJ. Effects of NADH on dopamine release in rat striatum. Synapse. 2000; 36: 95-101.
8. Tanner CM. The role of environmental toxines in the etiology of Parkinson's disease. Trends Neurosci. 1989; 12: 49-54.
9. Gershanik OS, Luquin MR, Scipioni O, Obeso JA. Isoniazid therapy in Parkinson's disease. Mov Disord. 1988; 3: 133-139.
10. Fujii C, Harada S, Ohkoshi N, Hayashi A, Yoshizawa K. Study on Parkinson's disease and alcohol drinking. Nihon Arukoru Yakubutsu Igakkai Zasshi. 1998; 33: 683-691.
11. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW. Parkinson disease in twins: an etiologic study. JAMA. 1999; 281: 341-346.
12. Baptista MJ, Cookson MR, Miller DW. Parkin and alpha-synuclein: opponent actions in the pathogenesis of Parkinson's disease. Neuroscientist. 2004; 10: 63-72.
13. Piccinin GL, Piccirilli M, Finali G, Stefano E. MPTP: a new chapter in the history of Parkinson's disease. Riv Neurol. 1989; 59: 103-107.
14. Williams AC, Pall HS, Steventon GB, Green S, Buttum S, Molloy H, Waring RH. N-methylation of pyridines and Parkinson's disease. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, editors. Advances in Neurology, vol. 60. New York: Raven Press, 1993: p. 194-196.
15. Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, Volk C, Arndt P, Ulzheimer JC, Sonders MS, Baumann C, Waldegger S, Lang F, Koepsell H. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998; 54: 342-352.
16. Köppen A, Klein J, Holler T, Löffelholz K. Synergistic effect of nicotinamide and choline administration on extracellular choline levels in the brain. J Pharmacol Exp Ther. 1993; 266: 720-725.
17. 1- methylnicotinamide in brain tissue. Life Sci. 1996; 58: 1995-2002.
18. Orth M, Schapira AHV. Mitochondria and degenerative disorders. Am J Med Genet. 2001; 106: 27-36.
19. Schulz JB, Matthews RT, Klockgether T, Dichgans J, Beal MF. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol Cell Biochem. 1997; 174: 193-197.
20. Kosel S, Hofhaus G, Maassen A, Vieregge P, Graeber MB. Role of mitochondria in Parkinson disease. Biol Chem. 1999; 380: 865-870.
21. Tanaka M, Kovalenko SA, Gong JS, Borgeld HJ, Katsumata K, Hayakawa M, Yoneda M, Ozawa T. Accumulation of deletions and point mutations in mitochondrial genome in degenerative diseases. Ann N Y Acad Sci. 1996; 786: 102-111.
22. Parker Jr WD, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol. 1989; 26: 719-723.
23. 1 reductase (complex I) in Parkinson's disease. J Neurochem. 1990; 55: 2142-2145.
24. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JP Jr, Davis RE, Parker WD Jr. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol. 1996; 40: 663-671.
25. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun. 1989; 163: 1450-1455.
26. van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Goetz CG, Small GW, Mastaglia F, Stajich JM, McLaurin AC, Middleton LT, Scott BL, Schmechel DE, Pericak-Vance MA, Vance JM. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet. 2003; 72: 804-811.
27. DiDonato S, Zeviani M, Giovannini P, Savarese N, Rimoldi M, Mariotti C, Girotti F, Caraceni T. Respiratory chain and mitochondrial DNA in muscle and brain in Parkinson's disease patients. Neurology. 1993; 43: 2262-2268.
28. Sandy MS, Langston JW, Smith MT, Di Monte DA. PCR analysis of platelet mtDNA: lack of specific changes in Parkinson's disease. Mov Disord. 1993; 8: 74-82.
29. Zhang J, Pieper A, Snyder SH. Poly(ADP-ribose) synthetase activation: an early indicator of neurotoxic DNA damage. J Neurochem. 1995; 65: 1411-1414.
30. Pieper AA, Verma A, Zhang J, Snyder SH. Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci. 1999; 20: 171-181.
31. Boulu RG, Mesenge C, Charriaut-Marlangue C, Verrecchia C, Plotkine M. Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose) polymerase. Bull Acad Natl Med. 2001; 185: 555-563.
32. Brune B, Dimmeler S, Molina Y, Vedia L, Lapetina EG. Nitric oxide: a signal for ADP-ribosylation of proteins. Life Sci. 1994; 54: 61-70.
33. Dimmeler S, Brune B. Characterization of a nitric-oxide-catalysed ADP-ribosylation of glyceraldehyde-3-phosphate dehydrogenase. Eur J Biochem. 1992; 210: 305-310.
34. Zhang J, Snyder SH. Nitric oxide stimulates auto-ADP-ribosylation of glyceraldehyde-3-phosphate dehydrogenase. Proc Natl Acad Sci U S A. 1992; 89: 9382-9385.
35. Lo EH, Bosque-Hamilton P, Meng W. Inhibition of poly(ADP-ribose) polymerase: reduction of ischemic injury and attenuation of N-methyl-D- aspartate-induced neurotransmitter dysregulation. Stroke. 1998; 29: 830-836.
36. Takahashi K, Pieper AA, Croul SE, Zhang J, Snyder SH, Greenberg JH. Post-treatment with an inhibitor of poly(ADP-ribose) polymerase attenuates cerebral damage in focal ischemia. Brain Res. 1999; 829: 46-54.
37. Hageman GJ, Stierum RH, van Herwijnen MH, van der Veer MS, Kleinjans JC. Nicotinic acid supplementation: effects on niacin status, cytogenetic damage, and poly(ADP-ribosylation) in lymphocytes of smokers. Nutr Cancer. 1998; 32: 113-120.
38. Mandir AS, Przedborski S, Jackson-Lewis V, Wang ZQ, Simbulan-Rosenthal CM, Smulson ME, Hoffman BE, Guastella DB, Dawson VL, Dawson TM. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci U S A. 1999; 96: 5774-5779.
39. Cosi C, Colpaert F, Koek W, Degryse A, Marien M. Poly(ADP-ribose) polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57B1/6 mice. Brain Res. 1996; 729: 264-269.
40. + and ATP induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide. Brain Res. 1998; 809: 58-67.
41. 1- methylnicotinamide in rats. Agric Biol Chem. 1986; 50: 1489-1493.
42. Sano A, Endo N, Takitani S. Fluorometric assay of rat tissue N-methyltransferases with nicotinamide and four isomeric methylnicotinamides. Chem Pharm Bull. 1992; 40: 153-156.
43. Seifert R, Hoshino J, Kröger H. Nicotinamide methylation: tissue distribution, development and neoplastic changes. Biochim Biophys Acta. 1984; 801: 259-264.
44. Fukushima T, Kaetsu A, Lim H, Moriyama M. Possible role of 1-methylnicotinamide in the pathogenesis of Parkinson's disease. Exp Toxicol Pathol. 2002; 53: 469-473.
45. Matsubara K, Aoyama K, Suno M, Awaya T. N-methylation underlying Parkinson's disease. Neurotoxicol Teratol. 2002; 24: 593-598.
46. Parsons RB, Smith SW, Waring RH, Williams AC, Ramsden DB. High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson's disease. Neurosci Lett. 2003; 342: 13-16.
47. Willets JM, Lunec J, Williams AC, Griffiths HR. Neurotoxicity of nicotinamide derivatives; their role in the aetiology of Parkinson's disease. Biochem Soc Trans. 1993; 21: 299S.
48. Fukushima T, Tawara T, Isobe A, Hojo N, Shiwaku K, Yamane Y. Radical formation site of cerebral complex I and Parkinson's disease. J Neurosci Res. 1995; 42: 385-390.
49. Narabayashi H, Takeshige K, Minakami S. Alteration of inner-membrane components and damage to electron-transfer activities of bovine heart submitochondrial particles induced by NADPH-dependent lipid peroxidation. Biochem J. 1982; 202: 97-105.
50. Chomyn A, Mariottini P, Cleeter MW, Ragan CI, Matsuno-Yagi A, Hatefi Y, Doolittle RF, Attardi G. Six unidentified reading frames of human mitochondrial DNA encode components of the respiratory-chain NADH dehydrogenase. Nature. 1985; 314: 592-597.
51. Triepels RH, Van Den Heuvel LP, Trijbels JM, Smeitink JA. Respiratory chain complex I deficiency. Am J Med Genet. 2001; 106: 37-45.
52. th edition, Stamford: Appleton & Lange, 2000: p. 676-678.
53. Food and Agriculture Organization of the United Nations. Rome Declaration on World Food Security and World Food Summit Plan of Action. Technical background documents 1-5. 1996.
54. Cosnett JE, Bill PL. Parkinson's disease in blacks. Observations on epidemiology in Natal. S Afr Med J. 1988; 73: 281-283.
55. Lombard A, Gelfand M. Parkinson's disease in the African. Cent Afr J Med. 1978; 24: 5-8.
56. Kusumi M, Nakashima K, Harada H, Nakayama H, Takahashi K. Epidemiology of Parkinson's disease in Yonago City, Japan: comparison with a study carried out 12 years ago. Neuroepidemiology. 1996; 15: 201-207.
57. Fukushima T, Moriyama M. Com might prevent Parkinson's disease. Clin Nutr. 2001; 20: 559.
58. Fukushima T, Tanaka K, Ushijima K, Moriyama M. Retrospective study of preventive effect of maize on mortality from Parkinson's disease in Japan. Asia Pac J Clin Nutr. 2003; 12: 447-450.
59. National Nutrition Survey, Japan. The Ministry of Health and Welfare, Japan.